| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03855cdc9dd524726348876796e6c784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_684e0a090f3fe8265fb82f1e1c44a2db |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-61 |
| filingDate |
2019-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb198b581aca8816ed369172f4b477b2 |
| publicationDate |
2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019211074-A1 |
| titleOfInvention |
Methods for protein modification in pharmaceutical applications |
| abstract |
This disclosure provides methods to modify protein for pharmaceutical applications and reagents to treat disease such as pathogen infection and cancer. The method involves increasing the molecular weight of the protein by connecting multiple protein units with site specific conjugation to extend the in vivo half life. This disclosure also provides methods to construct affinity ligand in protein or aptamer form, which becomes active when they reach the treatment target, therefore provide higher specificity for treatment. |
| priorityDate |
2015-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |